全文获取类型
收费全文 | 381篇 |
免费 | 15篇 |
国内免费 | 8篇 |
专业分类
儿科学 | 6篇 |
妇产科学 | 5篇 |
基础医学 | 30篇 |
口腔科学 | 7篇 |
临床医学 | 31篇 |
内科学 | 96篇 |
皮肤病学 | 2篇 |
神经病学 | 2篇 |
特种医学 | 8篇 |
外科学 | 21篇 |
综合类 | 20篇 |
预防医学 | 33篇 |
眼科学 | 18篇 |
药学 | 36篇 |
肿瘤学 | 89篇 |
出版年
2024年 | 1篇 |
2023年 | 6篇 |
2022年 | 8篇 |
2021年 | 22篇 |
2020年 | 5篇 |
2019年 | 7篇 |
2018年 | 6篇 |
2017年 | 5篇 |
2016年 | 15篇 |
2015年 | 22篇 |
2014年 | 21篇 |
2013年 | 35篇 |
2012年 | 33篇 |
2011年 | 23篇 |
2010年 | 18篇 |
2009年 | 12篇 |
2008年 | 12篇 |
2007年 | 27篇 |
2006年 | 22篇 |
2005年 | 14篇 |
2004年 | 19篇 |
2003年 | 12篇 |
2002年 | 3篇 |
2001年 | 10篇 |
2000年 | 2篇 |
1999年 | 5篇 |
1998年 | 7篇 |
1997年 | 3篇 |
1996年 | 2篇 |
1995年 | 3篇 |
1994年 | 1篇 |
1993年 | 3篇 |
1992年 | 1篇 |
1991年 | 1篇 |
1989年 | 2篇 |
1988年 | 5篇 |
1986年 | 2篇 |
1984年 | 1篇 |
1983年 | 1篇 |
1980年 | 3篇 |
1977年 | 1篇 |
1965年 | 1篇 |
1959年 | 1篇 |
1951年 | 1篇 |
排序方式: 共有404条查询结果,搜索用时 15 毫秒
1.
2.
van Leth F Huisamen CB Badaro R Vandercam B de Wet J Montaner JS Hall DB Wit FW Lange JM;NN Study Group 《Journal of acquired immune deficiency syndromes (1999)》2005,38(3):296-300
BACKGROUND: The initial rate of plasma HIV-1 RNA (pVL) decline has been proposed as a marker of early efficacy of antiretroviral therapy (ART) and a possible predictor of late efficacy. We compared the rate of pVL decline in patients starting ART with nevirapine (NVP), efavirenz (EFV), or both drugs combined in addition to lamivudine (3TC) and stavudine (d4T). METHODS: Analysis of the viral decay constant (VDc) during the first 2 weeks of treatment in patients enrolled in the 2NN study who remained on allocated treatment. RESULTS: The median VDc (log10 copies per day, [interquartile range]) was similar for NVP (0.30 [0.25-0.36], EFV (0.31 [0.27-0.37]), and NVP + EFV (0.30 [0.27-0.36]). Patients with a baseline pVL >100,000 copies/mL were 8.7 (95% confidence interval [CI]: 6.2-12.3) times more likely to have a VDc >75th percentile. A high VDc was not associated with plasma drug concentration or with a decreased risk of virologic failure at week 48 after the start of therapy (hazard ratio = 0.8, 95% CI: 0.6-1.2). CONCLUSION: NVP, EFV, or NVP + EFV in combination with 3TC and d4T show similar rates of pVL decline during the first 2 weeks of treatment. The VDc with these regimens is not predictive of late virologic efficacy. 相似文献
3.
Manojkumar Bupathi Ahmed Kaseb Funda Meric-Bernstam Aung Naing 《Molecular oncology》2015,9(8):1501-1509
Hepatocellular carcinoma (HCC) is a complex and heterogeneous tumor most commonly associated with underlying chronic liver disease, especially hepatitis. It is a growing problem in the United States and worldwide. There are two potential ways to prevent HCC. Primary prevention which is based on vaccination or secondary prevention involving agents that slow down carcinogenesis. Several pathways have been thought to play a role in the development of HCC; specifically, those involving vascular endothelial growth factor (VEGF)‐mediated angiogenesis, WNT, phosphatidylinositol 3‐kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR), AMP‐activated protein kinase (AMPK), and c‐MET. Currently, there are only a limited number of drugs which have been proven as effective treatment options for HCC and several clinical trials are testing drugs which target aberrations in the pathways mentioned above. In this review, we discuss currently approved therapies, monotherapies and combination therapy for the treatment of HCC. 相似文献
4.
5.
6.
Gregory J. Walker Zin Naing Alberto Ospina Stella Malinna Yeang Joanna Caguicla Vidiya Ramachandran Sonia R. Isaacs David Agapiou Rowena A. Bull Sacha Stelzer-Braid James Daly Iain B. Gosbell Veronica C. Hoad David O. Irving Joanne M. Pink Stuart Turville Anthony D. Kelleher William D. Rawlinson 《Viruses》2021,13(2)
Serological testing for SARS-CoV-2-specific antibodies provides important research and diagnostic information relating to COVID-19 prevalence, incidence and host immune response. A greater understanding of the relationship between functionally neutralising antibodies detected using microneutralisation assays and binding antibodies detected using scalable enzyme immunoassays (EIA) is needed in order to address protective immunity post-infection or vaccination, and assess EIA suitability as a surrogate test for screening of convalescent plasma donors. We assessed whether neutralising antibody titres correlated with signal cut-off ratios in five commercially available EIAs, and one in-house assay based on expressed spike protein targets. Sera from recovered patients or convalescent plasma donors who reported laboratory-confirmed SARS-CoV-2 infection (n = 200), and negative control sera collected prior to the COVID-19 pandemic (n = 100), were assessed in parallel. Performance was assessed by calculating EIA sensitivity and specificity with reference to microneutralisation. Neutralising antibodies were detected in 166 (83%) samples. Compared with this, the most sensitive EIAs were the Cobas Elecsys Anti-SARS-CoV-2 (98%) and Vitros Immunodiagnostic Anti-SARS-CoV-2 (100%), which detect total antibody targeting the N and S1 antigens, respectively. The assay with the best quantitative relationship with microneutralisation was the Euroimmun IgG. These results suggest the marker used (total Ab vs. IgG vs. IgA) and the target antigen are important determinants of assay performance. The strong correlation between microneutralisation and some commercially available assays demonstrates their potential for clinical and research use in assessing protection following infection or vaccination, and use as a surrogate test to assess donor suitability for convalescent plasma donation. 相似文献
7.
Phan Derek Q. Goitia Jesse Lee Ming-Sum Gupta Nigel Aharonian Vicken Mansukhani Prakash Moore Naing Brar Somjot S. Zadegan Ray 《Journal of interventional cardiac electrophysiology》2021,61(2):365-374
Journal of Interventional Cardiac Electrophysiology - Conduction disturbances after transcatheter aortic valve replacement (TAVR) requiring pacemaker (PPM) implantation are a known complication and... 相似文献
8.
9.
Naomi Takeichi Sanae Midorikawa Atsushi Watanabe Banyar Than Naing Hideki Tamura Toshiko Wakakuri‐Kano Akira Ishizaki Hitoshi Sugihara Sumiko Nissato Yuria Saito Yuichi Aita Kiyo‐aki Ishii Takehito Igarashi Yasushi Kawakami Hisato Hara Tatsuhiko Ikeda Kazuo Shimizu Shinichi Suzuki Hitoshi Shimano Masashi Kawamoto Takashi Shimada Tsuyoshi Watanabe Shinichi Oikawa Kazuhiro Takekoshi 《Clinical endocrinology》2012,77(5):707-714
10.